Flunarizine Tablet: Clinical Overview
Primary Indication
Flunarizine is a second-line prophylactic agent for migraine prevention, particularly effective in patients who have failed or cannot tolerate first-line therapies like beta-blockers or topiramate. 1
Dosing Regimen
- Standard adult dose: 5-10 mg orally once daily at bedtime 1
- Start with 5 mg daily and titrate based on response and tolerability
- In children: 5 mg daily is the typical starting dose 2
- Treatment duration should be at least 2-3 months to assess efficacy 3
- After achieving stability (typically 6-12 months), consider tapering or discontinuing 1
The 10 mg daily dose has been most extensively studied and shows consistent efficacy, with a 66.9% reduction in migraine severity scores 4. Doses up to 15 mg are generally well tolerated 5.
Specific Clinical Contexts
Hemiplegic Migraine
Flunarizine demonstrates particularly high efficacy in hemiplegic migraine variants, with 85% response rate in hemiplegic migraine versus 51% in non-hemiplegic forms 2. This makes it an especially valuable option for sporadic or familial hemiplegic migraine.
Pregnancy and Lactation
Flunarizine is contraindicated during pregnancy and breastfeeding - it is not mentioned among safe options in pregnancy, where propranolol or amitriptyline are preferred 1.
Contraindications
Absolute contraindications:
- Parkinsonism or history of extrapyramidal disorders
- Depression or history of significant mood disorders 1
- Pregnancy and lactation
These contraindications are critical because flunarizine can precipitate or worsen these conditions, particularly in elderly patients 3.
Common Adverse Effects
The most frequent adverse effects include:
- Sedation/drowsiness (most common, particularly early in treatment) 3, 4
- Weight gain/increased appetite (reported in 5-21% of patients) 3, 5, 2
- Depression (serious concern: 6-8% incidence, leading to discontinuation) 6, 2
- Extrapyramidal symptoms (rare but serious, especially in elderly) 3
In clinical practice, approximately 10.5-21% of patients discontinue treatment due to adverse effects, with depression and weight gain being the primary reasons 5, 2. The incidence of side effects tends to decrease after the first few months of treatment 4.
Efficacy Profile
Flunarizine reduces migraine attack frequency by approximately 0.4 attacks per 4 weeks compared to placebo 7. Its effectiveness is comparable to propranolol, with both drugs reducing migraine days by approximately 37% 6, 7. Success rate (≥50% reduction in attack frequency) is achieved in 57% of patients overall 2.
Clinical Positioning
Flunarizine ranks as second-line therapy in current guidelines 1, behind:
- First-line agents: Propranolol, timolol, metoprolol, bisoprolol, atenolol, topiramate, divalproex sodium 1, 3
Consider flunarizine when:
- First-line beta-blockers or anticonvulsants are contraindicated or ineffective
- Patient has hemiplegic migraine (where it shows superior efficacy)
- Patient cannot tolerate other preventive medications
- Asthma or cardiac conditions preclude beta-blocker use
Critical Monitoring Points
- Screen for depression before initiating and monitor mood throughout treatment - this is the most serious adverse effect requiring discontinuation
- Monitor weight regularly, especially in the first 3-6 months
- Assess for sedation, which typically improves with continued use
- In elderly patients, be vigilant for extrapyramidal symptoms
- Evaluate treatment response at 2-3 months; if ineffective, consider alternative prophylaxis 1, 3
Practical Considerations
The drug is widely used in Europe and has over 20 years of clinical experience in specialized headache centers 5. While not licensed in some countries (including the UK), it has supportive evidence from NICE guidelines and is considered as effective as propranolol and topiramate 5. The benefit-risk profile supports its use as a valuable second-line option, particularly when first-line agents have failed 3, 8.